Last reviewed · How we verify

SUP Lidocaine

University of Michigan · FDA-approved active Small molecule

SUP Lidocaine is a topical formulation of lidocaine, a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

SUP Lidocaine is a topical formulation of lidocaine, a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Localized pain relief (specific indication dependent on SUP formulation type).

At a glance

Generic nameSUP Lidocaine
Also known asGeneric lidocaine (Henry Schein Inc)
SponsorUniversity of Michigan
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain management / Anesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine works by inhibiting the influx of sodium ions through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and blocking the generation and conduction of action potentials. This results in local anesthesia at the site of application. The SUP formulation (likely a suppository or specialized delivery system) allows for localized pain relief in specific anatomical regions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: